AU2007274288B2 — Combination of adapalene and benzoyl peroxide for treating acne lesions
Assigned to Galderma Research and Development SNC · Expires 2013-05-02 · 13y expired
What this patent protects
The invention relates to the use of adapalene or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO). Th…
USPTO Abstract
The invention relates to the use of adapalene or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO). The recommended treatment may take the form of a pharmaceutical composition combining adapalene and BPO or a concomitant application of two pharmaceutical compositions, one comprising adapalene and the other comprising BPO.
Drugs covered by this patent
- Differin (ADAPALENE) · Galderma Labs Lp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.